RESUMEN
Smokers (n = 315) who wished to quit were randomly assigned in a double-blind manner to groups using either nicotine or placebo gum. Self-reported and observed symptoms of tobacco withdrawal were collected before cessation and at follow-ups of 1 to 2 weeks, 1 month, and 6 months. Self-reported and/or observed anger, anxiety, craving, difficulty concentrating, hunger, impatience, and restlessness were the most prominent symptoms of tobacco withdrawal. These symptoms had returned to precessation levels by 1 month except increased weight, hunger, and craving continued for 6 months in many smokers. Nicotine gum decreased most symptoms, including craving and hunger but not weight. Abstinent smokers with more intense withdrawal were not more likely to relapse. Abstinent smokers who gained more weight were less likely to relapse.
Asunto(s)
Goma de Mascar , Nicotina/análogos & derivados , Nicotina/efectos adversos , Ácidos Polimetacrílicos/uso terapéutico , Polivinilos/uso terapéutico , Prevención del Hábito de Fumar , Síndrome de Abstinencia a Sustancias/diagnóstico , Adulto , Femenino , Humanos , Hambre , Masculino , Nicotina/uso terapéutico , Placebos , Fumar/psicología , Síndrome de Abstinencia a Sustancias/etiología , Trastornos Relacionados con Sustancias/complicaciones , Dispositivos para Dejar de Fumar Tabaco , Aumento de PesoRESUMEN
This study prospectively examined withdrawal symptoms in persons using Copenhagen smokeless tobacco and in persons smoking cigarettes. Smokeless tobacco chewers (N = 16) and cigarette smokers (N = 11) were examined during a 6-day period, during which time a number of measures were administered. Subjects used smokeless tobacco or smoked cigarettes on an ad libitum basis for a 3-day baseline period and then underwent tobacco deprivation. The significant changes that occurred relative to baseline after smokeless tobacco deprivation included decreased heart rate and orthostatic pulse change and increased craving for tobacco, confusion, eating, number of awakenings, and total scores on a withdrawal symptoms checklist for both self-rated and observer-rated measures. There were more changes and changes of greater severity among cigarette smokers.
Asunto(s)
Nicotiana , Plantas Tóxicas , Síndrome de Abstinencia a Sustancias/fisiopatología , Tabaco sin Humo , Adulto , Cotinina/análisis , Humanos , Masculino , Saliva/análisis , Fumar , Estadística como Asunto , Síndrome de Abstinencia a Sustancias/psicologíaRESUMEN
The nicotine metabolite cotinine was administered to abstinent cigarette smokers to determine whether it has pharmacologic activity as assessed by various physiologic and subjective measurements. By means of a randomized, double-blind, placebo-controlled counterbalanced-order design, subjects received cotinine base (30 mg) intravenously after 48 hours of abstinence from cigarette smoking. Serum cotinine concentrations increased to levels commonly achieved during daily cigarette smoking, whereas no change in serum nicotine concentration was observed. Cotinine compared with placebo produced subjective differences in self-reported ratings of restlessness, anxiety and tension, insomnia, sedation, and pleasantness. Cotinine had minimal effects on cardiovascular measurements. These findings indicate that cotinine is behaviorally active in the setting of cigarette abstinence at blood concentrations similar to those commonly achieved through daily cigarette smoking.
Asunto(s)
Afecto/efectos de los fármacos , Cotinina/farmacología , Cese del Hábito de Fumar , Síndrome de Abstinencia a Sustancias/tratamiento farmacológico , Adulto , Cotinina/administración & dosificación , Método Doble Ciego , Humanos , Inyecciones Intravenosas , MasculinoRESUMEN
A series of novel nonpeptide angiotensin II receptor antagonists containing a substituted (E)-acrylic acid has been developed. The overlay of 1, an imidazole-5-acetic acid found in the patent literature, on a novel pharmacophore model of AII suggested that extension of the acid side chain and attachment of a second aryl residue to mimic the C-terminal phenylalanine region of AII would lead to increased activity. A study of extended acid side chains at C-5 of the imidazole nucleus led to the discovery of the (E)-acrylic acid 5 as a promising starting point for further exploration. As predicted by the modeling, substitution of a benzyl group on the acrylic acid side chain to mimic the phenylalanine gave increased potency. An extensive study of the SAR of the newly introduced aromatic ring revealed that electron-rich heteroaryl rings provided improved activity, most notably in the in vivo rat models. Compound 40, (E)-3-[2-butyl-1- [(2-chlorophenyl)methyl]imidazol-5-yl]-2-[(2-thienyl)methyl]-2- propenoic acid, has been shown to be a potent, competitive, and orally active small molecule AT-1 receptor antagonist. It exhibits a 2 orders of magnitude increase in binding affinity and a 10-fold improvement in in vivo potency as compared to compound 1 and represents an important milestone in the development of even more potent nonpeptide angiotensin II receptor antagonists.
Asunto(s)
Acrilatos/farmacología , Antagonistas de Receptores de Angiotensina , Imidazoles/farmacología , Acrilatos/química , Animales , Diseño de Fármacos , Imidazoles/química , Técnicas In Vitro , Masculino , Conejos , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Difracción de Rayos XRESUMEN
The further evolution of the imidazole-5-acrylic acid series of nonpeptide angiotensin II receptor antagonists is detailed (for Part 1, see: J. Med. Chem. 1992, 35, 3858). Modifications of the N-benzyl ring substitution were undertaken in an effort to mimic the Tyr4 residue of angiotensin II. Introduction of a p-carboxylic acid on the N-benzyl ring resulted in the discovery of compounds with nanomolar affinity for the receptor and good oral activity. SAR studies of these potent antagonists revealed that the thienyl ring, the (E)-acrylic acid, and the imidazole ring in addition to the two acid groups were important for high potency. Also, overlay comparisons of the parent diacid with both angiotensin II and a representative biphenylyltetrazole nonpeptide angiotensin II receptor antagonist are presented. The parent diacid analog, SK&F 108566 or (E)-3-[2-butyl-1-(4-carboxybenzyl)-1H-imidazole-5-yl]-2-[(2- thienyl)methyl]propenoic acid, is currently in clinical development for the treatment of hypertension.
Asunto(s)
Acrilatos/síntesis química , Acrilatos/farmacología , Antagonistas de Receptores de Angiotensina , Imidazoles/síntesis química , Imidazoles/farmacología , Tiofenos , Secuencia de Aminoácidos , Angiotensina II/antagonistas & inhibidores , Animales , Técnicas In Vitro , Modelos Moleculares , Datos de Secuencia Molecular , Conejos , Ratas , Relación Estructura-ActividadRESUMEN
High-throughput screening for the induction of a luciferase reporter gene in a thrombopoietin (TPO)-responsive cell line resulted in the identification of 4-diazo-3-hydroxy-1-naphthalenesulfonic acids as TPO mimics. Modification of the core structure and adjustment of unwanted functionality resulted in the development of (5-oxo-1,5-dihydropyrazol-4-ylidene)hydrazines which exhibited efficacies equivalent to those of TPO in several cell-based assays designed to measure thrombopoietic activity. Furthermore, these compounds elicited biochemical responses in TPO-receptor-expressing cells similar to those in TPO itself, including kinase activation and protein phosphorylation. Potencies for the best compounds were high for such low molecular weight compounds (MW < 500) with EC(50) values in the region of 1-20 nM.
Asunto(s)
Compuestos Azo/síntesis química , Hidrazinas/síntesis química , Megacariocitos/efectos de los fármacos , Naftalenosulfonatos/síntesis química , Proteínas de Neoplasias , Pirazoles/síntesis química , Receptores de Citocinas , Trombopoyetina/química , Animales , Compuestos Azo/química , Compuestos Azo/farmacología , División Celular , Línea Celular , Evaluación Preclínica de Medicamentos , Ensayo de Cambio de Movilidad Electroforética , Activación Enzimática , Genes Reporteros , Hidrazinas/química , Hidrazinas/farmacología , Luciferasas/genética , Luciferasas/metabolismo , Ratones , Imitación Molecular , Peso Molecular , Naftalenosulfonatos/química , Naftalenosulfonatos/farmacología , Fosforilación , Fosfotransferasas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Pirazoles/química , Pirazoles/farmacología , Receptores de Trombopoyetina , Relación Estructura-Actividad , Trombopoyetina/metabolismoRESUMEN
Previously, we reported the direct design of highly potent nonpeptide 3-oxo-1,4-benzodiazepine fibrinogen receptor antagonists from a constrained, RGD-containing cyclic semipeptide. The critical features incorporated into the design of these nonpeptides were the exocyclic amide at the 8-position which overlaid the Arg carbonyl, the phenyl ring which maintained an extended Gly conformation, and the diazepine ring which mimicked the gamma-turn at Asp. In this paper, we investigate conformational preferences of the 8-substituted benzodiazepine analogues by examining structural modifications to both the exocyclic amide and the seven-membered diazepine ring and by studying the conformation of the benzodiazepine ring using molecular modeling, X-ray crystallography, and NMR. We found that the directionality of the amide at the 8-position had little effect on activity and the (E)-olefin analogue retained significant potency, indicating that the trans orientation of the amide, and not the carbonyl or NH groups, made the largest contribution to the observed activity. For the diazepine ring, with the exception of the closely analogous 3-oxo-2-benzazepine ring system described previously, all of the modifications led to a significant reduction in activity compared to the potent 3-oxo-1, 4-benzodiazepine parent ring system, implicating this particular type of ring system as a desirable structural feature for high potency. Energy minimizations of a number of the modified analogues revealed that none could adopt the same low-energy conformation as the one shared by the active (S)-isomer of the 3-oxo-1, 4-benzodiazepines and 3-oxo-2-benzazepines. The overall data suggest that the features contributing to the observed high potency in this series are the orientation of the 3-4 amide and the conformational constraint imposed by the seven-membered ring, both of which position the key acidic and basic groups in the proper spatial relationship.
Asunto(s)
Benzodiazepinas/síntesis química , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/antagonistas & inhibidores , Benzodiazepinas/química , Benzodiazepinas/metabolismo , Benzodiazepinas/farmacología , Cristalografía por Rayos X , Humanos , Técnicas In Vitro , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Conformación Molecular , Agregación Plaquetaria/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/síntesis química , Inhibidores de Agregación Plaquetaria/química , Inhibidores de Agregación Plaquetaria/metabolismo , Inhibidores de Agregación Plaquetaria/farmacología , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Relación Estructura-ActividadRESUMEN
There is an increasing prevalence of smokeless tobacco use. However, very little descriptive information is available on the pattern of use. This study examines topographical features of smokeless tobacco use in a male college-age population (N = 56). Subjects were required to use smokeless tobacco ad lib. for a period of 3 days. During this time, they were asked to record the time of onset and completion of each dip of smokeless tobacco. Smokeless tobacco use was significantly associated with time of day. The mean dips/day was 6.3 (SD +/- 2.2), mean inter-dip interval was 102.6 (SD +/- 42.1) min, mean duration/dip was 39.9 (SD +/- 16.5)min, and mean total dip duration/day was 254.6 (SD +/- 129.3) min. The mean grams of tobacco/dip was 1.97 (SD +/- 0.96) and the total grams of tobacco used/day was 12.0 (SD +/- 6.8) g. There were significant correlations between saliva cotinine and number of dips/day, mean duration/dip, total dip duration/day and mean inter-dip interval, suggesting that smokeless tobacco has the potential for producing dependence.
Asunto(s)
Nicotiana , Plantas Tóxicas , Tabaquismo/epidemiología , Tabaco sin Humo , Adolescente , Adulto , Humanos , Masculino , Estados UnidosRESUMEN
Several past studies have reported reliable changes in reaction time performance and self-rated withdrawal scores as a consequence of cigarette deprivation. The purpose of the present study was to determine, prospectively, the effect 24 h of smokeless tobacco deprivation in regular users has on performance and the associated withdrawal symptomology. Forty smokeless tobacco users (Copenhagen brand) were randomly divided evenly into two groups (N = 20):24 h of deprivation and no deprivation. A third group of ten nonchewers was added as another control group. The results indicated that behavioral, subjective and physiological changes are associated with smokeless tobacco deprivation in regular users. These include increased craving scores, reaction time, self-rated withdrawal symptoms and decreased heart rate.
Asunto(s)
Nicotiana , Plantas Tóxicas , Desempeño Psicomotor/efectos de los fármacos , Síndrome de Abstinencia a Sustancias/psicología , Tabaco sin Humo , Adulto , Afecto/efectos de los fármacos , Cotinina/sangre , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Tiempo de Reacción/efectos de los fármacosRESUMEN
Few studies have examined the association between ethanol use and cigarette smoking topography. In particular, no study has objectively investigated the relationship between chronic ethanol exposure and cigarette smoking. The aim of this study was to quantify the relationship between cigarette smoking and past and current ethanol use. Male and female cigarette smokers (n = 77) between the ages of 30 and 65 years were recruited and grouped as a function of their past and current ethanol use. Group 1 (n = 18) included subjects who were ethanol abstinent for the 3 months prior to the study and had no history of alcohol abuse (as defined by DSM-III criteria). Group 2 (n = 19) included subjects who were current regular ethanol users and had no history of alcohol abuse. Group 3 (n = 20) included subjects who were ethanol abstinent and had a history of alcohol abuse. Group 4 (n = 20) included current regular ethanol users with a history of alcohol abuse. A history of alcohol abuse was associated with an intensified pattern of cigarette smoking. Significant differences were observed for total daily smoke exposure, cigarette number, puff number, total puff and inhalation volume, and the nicotine, tar and carbon monoxide yields of the cigarettes smoked. Increased expired-air carbon monoxide and serum cotinine levels were also observed. Current ethanol use was not associated with an increased cigarette smoking pattern. These data suggest that alcohol abusers are at greater risk of contracting cigarette-related pathology.
Asunto(s)
Alcoholismo/psicología , Etanol/farmacología , Fumar/psicología , Adulto , Anciano , Interacciones Farmacológicas , Ambiente , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
It is well established that nicotine meets all criteria of a highly addictive drug. However, as recognized by the U.S. surgeon general, the nicotine delivery system itself is an important determinant of the toxic and addictive effects engendered by nicotine use. Therefore, altering the form of nicotine dosing may allow for selective therapeutic action in efforts to develop safer and less addictive nicotine replacement therapies. While it is the case that initial tobacco use often escalates to compulsive use accompanied by tolerance and physical dependence, this is not usually observed with nicotine replacement therapies. These observations are consistent with laboratory data indicating that (a) nicotine polacrilex and transdermal systems deliver nicotine more slowly and at lower dose levels than tobacco-based forms, and (b) human data suggesting that the abuse liability of these systems is substantially lower than that of the tobacco-based nicotine delivery systems. Because the drug dosage form can be systematically manipulated and evaluated, further research in developing alternative nicotine delivery forms may hold substantial promise in the treatment of tobacco dependence. Psychological research methods can play an important part in their evaluation.
Asunto(s)
Nicotina/administración & dosificación , Fumar/psicología , Administración Cutánea , Administración por Inhalación , Administración Oral , Relación Dosis-Respuesta a Droga , Humanos , Nicotina/efectos adversos , Nicotina/farmacocinética , Fumar/efectos adversos , Fumar/sangre , Síndrome de Abstinencia a Sustancias/sangreRESUMEN
Health hazards associated with nicotine and tobacco use are well known. A contributing factor, the dependence producing potential of this drug, has become widely accepted. However, there are only a few human and animal studies that provide objective measures of the behavioral consequences of nicotine abstinence. The purpose of the present experiment was to use sensitive measures to examine behavioral disruptions that resulted when nicotine administration was terminated. Six rats were administered 96 daily intravenous infusions of nicotine (0.125 mg/kg/infusion) for at least 10 days. They were trained to respond on a tongue-operated solenoid-driven drinking device that delivered 0.005 ml of a glucose and saccharin solution (G + S) per lick. When nicotine access was terminated for six days, there was a marked suppression in behavior reinforced by the sweetened solution, and this disruption was immediately reversed when nicotine was reinstated. In contrast, nicotine removal also resulted in a decrease in food intake on the first day, but on subsequent days food intake was significantly higher than when nicotine was administered. When cotinine (0.25 mg/kg/infusion), a metabolite of nicotine was substituted for nicotine for six days, similar disruptions resulted in responding maintained by G + S, but food intake was not significantly decreased on the first day of nicotine abstinence. These findings illustrate the utility of sensitive behavioral tests to reveal effects of nicotine abstinence.
Asunto(s)
Conducta Animal/efectos de los fármacos , Nicotina/efectos adversos , Síndrome de Abstinencia a Sustancias/psicología , Animales , Cotinina/farmacología , Conducta de Ingestión de Líquido/efectos de los fármacos , Conducta Alimentaria/efectos de los fármacos , Ratas , Ratas EndogámicasRESUMEN
Relationships were explored among the frequencies of use of various drugs by a sample of drug-abusing clients of the Addiction Research Foundation (ARF) in Toronto and by drug abusers volunteering to participate in research at the Addiction Research Center (ARC) in Baltimore. The two groups of drug-abusing individuals differed in a number of characteristics. Those from ARF were admitted primarily for diagnosis and possible treatment for alcohol and non-opioid drug problems, whereas those from the ARC were admitted for participation in research on other drugs of abuse, primarily involving opioids. Patterns of use of certain drugs tended to covary in both groups. Of particular interest was the finding that severity of alcoholism was directly related to various measures of tobacco and caffeinated beverage use. In contrast, there was little correlation between the frequency of use among other drugs of abuse (e.g., heroin, cannabis, glue) and the use of tobacco and caffeine. These findings suggest that dependence on nicotine, caffeine, and alcohol may be governed by the same factors and possibly should be considered jointly in the treatment of alcoholic persons. Frequency of use of other drugs examined may be controlled by other factors than those which determine level of use of tobacco and caffeine.
Asunto(s)
Alcoholismo/epidemiología , Cafeína , Drogas Ilícitas , Psicotrópicos , Cese del Hábito de Fumar , Fumar/epidemiología , Trastornos Relacionados con Sustancias/epidemiología , Adulto , Alcoholismo/rehabilitación , Baltimore/epidemiología , Comorbilidad , Estudios Transversales , Femenino , Humanos , Incidencia , Masculino , Ontario/epidemiología , Trastornos Relacionados con Opioides/epidemiología , Trastornos Relacionados con Opioides/rehabilitación , Trastornos Relacionados con Sustancias/rehabilitaciónRESUMEN
Sixteen smokers completed a sustained attention task, were randomly assigned to either continue smoking or abstain for 24 h, and were retested. Eight nonsmokers served as a control group. Abstinence increased the variability in responding. Abstinence also appeared to impair the ability to inhibit responding. Abstinence did not potentiate fatigue during the task. These results are consistent with reports that tobacco withdrawal increases difficulty concentrating and impatience but does not increase fatigue.
Asunto(s)
Atención/efectos de los fármacos , Nicotina/efectos adversos , Fumar/psicología , Síndrome de Abstinencia a Sustancias/psicología , Adulto , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Nicotina/administración & dosificación , Tiempo de Reacción/efectos de los fármacosRESUMEN
Although a variety of drugs have been detected in sweat, little information is available on the characteristics of drug excretion in sweat under controlled-dosing conditions. A series of clinical studies were designed to determine the identity, concentration, time course, dose dependency, and variability of drug and metabolite excretion in sweat following administration of single doses of cocaine and heroin to human subjects. Sweat was collected by means of a sweat patch that could be worn for a period of several days to several weeks at a time, resulting in accumulation of drug in the patch. Sweat patches were removed at specified times and frozen until analyzed by gas chromatography--mass spectrometry. Cocaine and heroin were the major analytes excreted in sweat following their administration. Smaller amounts of cocaine metabolites were also detected following cocaine administration. 6-Acetylmorphine appeared rapidly after heroin administration and continued to increase while heroin content decreased, suggesting that heroin was undergoing hydrolysis in the sweat patch. Cocaine appeared in sweat within 1-2 hours and peaked within 24 hours in an apparent dose-dependent manner. Analysis of duplicate adjacent patches from individual subjects who had been administered cocaine provided similar quantitative results, suggesting that intrasubject variability was relatively low, whereas intersubject variability was high. These observations regarding the excretion of cocaine and heroin analytes in sweat have important forensic implications to other fields such as hair analysis. Sweat excretion could be an important mechanism by which drugs enter hair. These data also suggest that the sweat patch could serve as a useful monitoring device in surveillance of individuals in treatment and probation programs.
Asunto(s)
Cocaína/metabolismo , Heroína/metabolismo , Sudor/química , Administración por Inhalación , Administración Intranasal , Cocaína/administración & dosificación , Humanos , Inyecciones Intravenosas , MasculinoRESUMEN
Despite the current popularity of smoking as a route of drug self-administration, there have been few human studies characterizing the pharmacokinetics and pharmacodynamics of smoked drugs of abuse. A variety of technological difficulties are encountered in the design of smoking studies, such as delivering reproducible doses and limiting the amount of pyrolysis of parent drug. As part of a concerted research effort to deliver precise, smoked doses of drug, a computer-assisted smoking device was utilized that delivered single puffs of heroin vapor to human subjects under controlled clinical conditions. Recovery studies indicated that the smoking device delivered approximately 89% of parent heroin to subjects. Although only two qualified heroin smokers could be identified as eligible volunteers, their participation provided the unique opportunity to study the pharmacokinetics and pharmacodynamics of smoked heroin. The two subjects were administered four smoked heroin doses in ascending order. In addition, four intravenous doses of heroin were administered for comparison of effects and estimation of bioavailability. Concurrent physiological, behavioral, and performance measures were collected along with blood samples. Blood was analyzed for heroin, 6-acetylmorphine, and morphine by solid-phase extraction gas chromatography-mass spectrometry. Heroin appeared rapidly in blood after administration and peaked 1-5 minutes after smoking, which is similar to that observed following intravenous administration. Heroin concentrations declined rapidly to the limit of detection (1.0 ng/mL) by 30 minutes. 6-Acetylmorphine blood concentrations also peaked and declined rapidly after smoked heroin with peak concentrations occurring at 1-2 minutes after smoking. Morphine levels rose and decayed more slowly. Mean elimination half-lives for heroin, 6-acetylmorphine, and morphine were 3.3 min, 5.4 min, and 18.8 min, respectively, by the smoked route. The bioavailability of smoked heroin was highly variable. Physiological measures such as pupil diameter demonstrated a counterclockwise hysteresis compared with heroin blood levels. The rapid onset of pharmacological effects together with the early appearance of heroin and metabolites in blood following smoked heroin demonstrated the effectiveness of this route of drug administration. It is evident that the smoking route enables individuals to obtain similar pharmacological effects as are produced by intravenous administration of heroin.